Glaukos Corporation (GKOS): Price and Financial Metrics


Glaukos Corporation (GKOS): $51.52

-0.96 (-1.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GKOS POWR Grades

  • Quality is the dimension where GKOS ranks best; there it ranks ahead of 56.94% of US stocks.
  • GKOS's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • GKOS ranks lowest in Sentiment; there it ranks in the 9th percentile.

GKOS Stock Summary

  • GKOS's price/sales ratio is 8.79; that's higher than the P/S ratio of 85.9% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, GLAUKOS CORP is reporting a growth rate of 198.94%; that's higher than 92.19% of US stocks.
  • As for revenue growth, note that GKOS's revenue has grown -3.1% over the past 12 months; that beats the revenue growth of just 20.44% of US companies in our set.
  • Stocks that are quantitatively similar to GKOS, based on their financial statements, market capitalization, and price volatility, are AAOI, EYPT, ONDS, MRIN, and TTNP.
  • Visit GKOS's SEC page to see the company's official filings. To visit the company's web site, go to www.glaukos.com.

GKOS Valuation Summary

  • In comparison to the median Healthcare stock, GKOS's price/sales ratio is 285.71% higher, now standing at 8.1.
  • Over the past 93 months, GKOS's EV/EBIT ratio has gone up 90.2.

Below are key valuation metrics over time for GKOS.

Stock Date P/S P/B P/E EV/EBIT
GKOS 2023-01-30 8.1 4.2 -25.7 -34.0
GKOS 2023-01-27 8.0 4.2 -25.6 -33.8
GKOS 2023-01-26 8.1 4.2 -25.6 -33.9
GKOS 2023-01-25 8.0 4.2 -25.5 -33.7
GKOS 2023-01-24 8.1 4.2 -25.6 -33.9
GKOS 2023-01-23 8.2 4.3 -26.2 -34.5

GKOS Growth Metrics

    The 3 year revenue growth rate now stands at 50.5%.
  • Its 5 year revenue growth rate is now at 87.32%.
  • The 3 year net income to common stockholders growth rate now stands at -139.57%.
Over the past 49 months, GKOS's revenue has gone up $116,023,000.

The table below shows GKOS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 284.875 -33.598 -89.607
2022-06-30 288.316 10.707 -55.801
2022-03-31 293.724 30.304 -27.747
2021-12-31 294.011 24.708 -49.593
2021-09-30 294.005 39.963 -38.369
2021-06-30 284.126 12.603 -60.347

GKOS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GKOS has a Quality Grade of C, ranking ahead of 54.76% of graded US stocks.
  • GKOS's asset turnover comes in at 0.279 -- ranking 135th of 186 Medical Equipment stocks.
  • FONR, ATRC, and BSX are the stocks whose asset turnover ratios are most correlated with GKOS.

The table below shows GKOS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.279 0.747 -0.076
2021-03-31 0.236 0.681 -0.129
2020-12-31 0.238 0.592 -0.218
2020-09-30 0.243 0.595 -0.310
2020-06-30 0.291 0.632 -0.400
2020-03-31 0.432 0.731 -0.328

GKOS Stock Price Chart Interactive Chart >

Price chart for GKOS

GKOS Price/Volume Stats

Current price $51.52 52-week high $64.49
Prev. close $52.48 52-week low $33.33
Day low $51.52 Volume 419,900
Day high $53.32 Avg. volume 389,061
50-day MA $46.10 Dividend yield N/A
200-day MA $48.58 Market Cap 2.46B

Glaukos Corporation (GKOS) Company Bio


Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.


GKOS Latest News Stream


Event/Time News Detail
Loading, please wait...

GKOS Latest Social Stream


Loading social stream, please wait...

View Full GKOS Social Stream

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22

ALISO VIEJO, Calif., February 01, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2022 financial results after the market close on Wednesday, February 22, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February

Yahoo | February 1, 2023

15 Largest Ophthalmology Companies in the World

In this article, we will take a look at the 15 largest ophthalmology companies in the world. If you want to see more companies in this selection, go to the 5 Largest Ophthalmology Companies in the World. The ophthalmology industry encompasses the diagnosis, treatment, and prevention of eye disorders and diseases. This includes medical and […]

Yahoo | January 31, 2023

Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

ALISO VIEJO, Calif., January 10, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive clinical updates for several of its Corneal Health pipeline programs, including the commencement of subject enrollment in a second Phase 3 confirmatory trial for Epioxa™ (Epi-on™), and promising initial results from the company’s Phase 2a clini

Yahoo | January 10, 2023

Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

ALISO VIEJO, Calif., January 10, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive results for a prospective, multi-center clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose® TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the Phase 2

Yahoo | January 10, 2023

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Yahoo | January 6, 2023

Read More 'GKOS' Stories Here

GKOS Price Returns

1-mo 14.06%
3-mo 5.53%
6-mo 2.28%
1-year -4.84%
3-year -18.93%
5-year 76.08%
YTD 17.95%
2022 -1.71%
2021 -40.95%
2020 38.17%
2019 -3.03%
2018 118.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8093 seconds.